ALSERES PHARMACEUTICALS INC /DE (ALSE) financial statements (2020 and earlier)

Company profile

Business Address 275 GROVE STREET
AUBURNDALE, MA 02466
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2014
TTM
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 01
Cash and cash equivalents 00
Short-term investments 01
Restricted cash and investments  0
Prepaid expense and other current assets0
Other undisclosed current assets 0 
Total current assets: 01
Noncurrent Assets
Property, plant and equipment  0
Deferred costs 00
Total noncurrent assets: 00
TOTAL ASSETS: 01
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 12
Other undisclosed accounts payable and accrued liabilities 12
Debt  7
Due to related parties 10
Deferred revenue and credits 00
Other liabilities 00
Other undisclosed current liabilities 0 
Total current liabilities: 210
Noncurrent Liabilities
Long-term debt and lease obligation 8 
Long-term debt, excluding current maturities 8 
Liabilities, other than long-term debt 11
Deferred revenue and credits 11
Other liabilities 00
Other undisclosed noncurrent liabilities  16
Total noncurrent liabilities: 917
Total liabilities: 1127
Stockholders' equity
Stockholders' equity attributable to parent, including: (11)(27)
Common stock 00
Additional paid in capital 189172
Accumulated other comprehensive income (loss) 0(0)
Retained earnings  0
Other undisclosed stockholders' equity attributable to parent (200)(199)
Other undisclosed stockholders' equity 00
Total stockholders' equity: (10)(26)
TOTAL LIABILITIES AND EQUITY: 01

Income statement (P&L) ($ in millions)

6/30/2014
TTM
12/31/2013
12/31/2012
Gross profit: 01
Operating expenses (1)(2)
Operating loss: (1)(1)
Nonoperating income 10
Investment income, nonoperating 00
Other nonoperating income 00
Interest and debt expense (0)(0)
Net income (loss): 0(2)
Other undisclosed net loss attributable to parent (1) 
Net loss available to common stockholders, diluted: (1)(2)

Comprehensive Income ($ in millions)

6/30/2014
TTM
12/31/2013
12/31/2012
Net income (loss): 0(2)
Comprehensive income (loss): 0(2)
Other undisclosed comprehensive loss, net of tax, attributable to parent (1) 
Comprehensive loss, net of tax, attributable to parent: (1)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: